EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS

Shilpa S Dhar, Calena Brown, Ali Rizvi, Lauren Reed, Sivareddy Kotla, Constantin Zod, Janak Abraham, Jun-Ichi Abe, Veena Rajaram, Kaifu Chen, Min Gyu Lee

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.115619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Shilpa S Dhar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. El…. Hauptthemen laut MEDLINE: Medulloblastoma, Histone Demethylases, Oxidative Phosphorylation, Enhancer Elements, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaHistone DemethylasesOxidative PhosphorylationEnhancer Elements, GeneticHistone-Lysine N-MethyltransferaseCerebellar NeoplasmsDNA-Binding ProteinsAnimalsMiceHeterozygoteCell Line, TumorHumansHistonesPatched-1 ReceptorGene Expression Regulation, NeoplasticMyeloid-Lymphoid Leukemia Protein

Stichwörter der Autor:innen

CP: CancerCP: MetabolismKMT2DLSD1NCOR2OXPHOSenhancerepigenetic modifierheterozygous losshistone methyltransferasemedulloblastomatumor suppressor

Substanzen

Histone DemethylasesKDM1a protein, mouseKmt2d protein, mouseHistone-Lysine N-MethyltransferaseDNA-Binding ProteinsHistonesPatched-1 ReceptorMyeloid-Lymphoid Leukemia Protein

Autor:innen und Institutionen

  • Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: ssdhar@mdanderson.org.
  • Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
  • Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
  • Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
  • Basic and Translational Research Division, Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: mglee@mdanderson.org.

Förderung

  • NCI NIH HHS
  • NICHD NIH HHS
  • University of Texas MD Anderson Cancer Center
  • Cancer Prevention and Research Institute of Texas
  • National Cancer Institute
  • Intellectual and Developmental Disabilities Research Center
  • Baylor College of Medicine
  • NIH

Zitieren

APA

Dhar, S. S., Brown, C., Rizvi, A., Reed, L., Kotla, S., Zod, C., Abraham, J., Abe, J. I., Rajaram, V., Chen, K., & Lee, M. G. (2025). Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115619

Vancouver

Dhar SS, Brown C, Rizvi A, Reed L, Kotla S, Zod C, et al. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115619

BibTeX
@article{Dhar2025,
  author = {Dhar, Shilpa S and Brown, Calena and Rizvi, Ali and Reed, Lauren and Kotla, Sivareddy and Zod, Constantin and Abraham, Janak and Abe, Jun-Ichi and Rajaram, Veena and Chen, Kaifu and Lee, Min Gyu},
  title = {Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.115619}
}
Kostenlos starten →